Clinical trials: SARS CoV 2 Infection
COVID-19, Sars-CoV-2 Infection
Efficacy and Safety of NVX-CoV2705
This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine.
- Trial name
- COVID-19 (NCT07086222)
- Testing
- NVX-CoV2705
- Where
- 99 sites in United States
- Volunteers
- 6,500 people, healthy volunteers welcome
- Sponsor
- Novavax
Anosmia
Investigating the Efficacy of OMT to Recover Olfactory Perception After COVID-19
One of the most widespread symptoms of COVID-19 is loss of the sense of smell. There are very few treatments for helping individuals recover their sense of smell.
- Trial name
- NCT06766279
- Testing
- Osteopathic Manipulative Treatment
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Burrell College of Health Sciences
COVID-19
Detection of COVID-19 Subjects Using DiaNose Exhalation Test
The study aim is to collect and analyze data of potential Volatile Organic Compounds (VOCs) that could be used for discriminating between patients with and without COVID-19 or with high-risk for COVID-19 by DiaNose breath test.
- Trial name
- NCT04476927
- Testing
- DiaNose
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nanose Medical Ltd.
In Utero SARS-CoV-2 Exposure
In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life
Since its initial outbreak in late 2019, coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 has ravaged the globe, causing illness characterized by inflammation and impaired oxygen levels.
- Trial name
- PROSPER (NCT04921241)
- Testing
- In Utero Exposure to SARS-CoV-2
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Vaccination Refusal, Communication
Emails Promoting COVID-19 Vaccination Among Healthcare Workers
In this evaluation, two versions of emails will be sent to Geisinger employees who have not been vaccinated against COVID-19. A delayed-contact control group will be emailed after a delay of at least two days.
- Trial name
- NCT04728594
- Testing
- Social Proof, Reframing, Scarcity Message
- Where
- United States
- Volunteers
- 9,566 people, healthy volunteers welcome
- Sponsor
- Geisinger Clinic
COVID-19 Pneumonia
COVID-19 Hyper Coagulability Care by LLLT
COVID-19 clotting Safety
- Trial name
- LLLT (NCT05271461)
- Testing
- Low level laser Therapy, Circulatory exercises
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cairo University
COVID-19, COVID-19 Immunisation
A Study to Evealuate Safety and Immunogenicity of TI-0010 SARS-CoV-2 Vaccine in Healthy Adults
This study is a randomized, double-blind, placebo controlled clinical exploratory study to evaluate the safety, tolerability and immunogenicity of TI-0010 vaccine in healthy adults aged 18-59.
- Trial name
- NCT06205524
- Testing
- TI-0010
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Drug Clinical Trial Institute of the Second Affiliated Hospital of Bengbu Medical College
COVID-19 Testing, Children, Preschool
Back to ECE Safely With SAGE: Reducing COVID-19 Transmission in Hispanic and Low-income Preschoolers
This study aims to get children safely back to school by (1) Child and Family Testing, (2) ECE Personnel Testing, and (3) Outdoor Learning via Garden Education.
- Conditions
- COVID-19 Testing, Children, Preschool, Parents, Child Development
- Trial name
- BESAGE (NCT05178290)
- Testing
- CHILD back-to-ECE COVID-19 saliva testing, ECE personnel back-to-ECE COVID-19 saliva screening, SAGE garden programming
- Where
- United States
- Volunteers
- 1,356 people, healthy volunteers welcome
- Sponsor
- Arizona State University
COVID-19
Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers
The primary objective was to assess the safety and tolerability of 2 different doses (10 or 30 µg) of GRT-R910 when administered as a boost in healthy adults previously vaccinated with the AstraZeneca, Janssen/Johnson and…
- Trial name
- NCT05148962
- Testing
- GRT-R910
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Gritstone bio, Inc.
COVID-19, Long COVID
CORona (COVID-19) Follow Up Study: Epidemiology, Pathophysiology, Prediction, and Communication
The CORFU study, funded by ZonMW, is a prospective, multiple, cohort study with a maximum follow-up of 24 months after COVID-19.
- Conditions
- COVID-19, Long COVID, Post COVID-19 Condition
- Trial name
- CORFU (NCT05240742)
- Testing
- no intervention, the CORFU study conducts analyses based on data which has been prospectively collected (and aggregated when possible) in 7 existing cohorts
- Where
- Netherlands
- Volunteers
- 4,291 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
SARS-CoV-2, COVID-19
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults.
- Trial name
- NCT05960097
- Testing
- CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose)
- Where
- 17 sites in United States, Australia
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
A Double-blind, Randomized, Controlled, Phase 2a Study to Evaluate the Safety and Tolerability of a Newcastle Disease Virus-based Mucosal Vaccine (NDV-HXP-S-KP.2) Relative to an Approved Systemic mRNA Vaccine in Previously…
- Trial name
- NCT07215520
- Testing
- NDV-HXP-S-KP.2, COVID-19 mRNA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- CastleVax Inc.
Inflammatory Disease, Rheumatoid Arthritis
Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19
People with inflammatory diseases are often treated with medications that act to suppress the immune-system, increasing the risk of catching infections.
- Conditions
- Inflammatory Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus
- Trial name
- OPINION (NCT05115370)
- Testing
- Semi-structured qualitative interview
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Covid19
Optimal Length for Nasal Mid-turbinate and Nasopharyngeal Swabs
This study aim to explore the optimal swap insertion length for mid-turbinate and nasopharyngeal samples. Our clinical trial took place at a Covid-19 test center in Copenhagen.
- Trial name
- NCT04840082
- Testing
- Nasopharyngeal swab for COVID-19 testing
- Where
- Denmark
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Covid19-associated ARDS, Covid19
A First-in-Human Study of AV-001 in Healthy Subjects
Phase 1 randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) first-in-human study in healthy subjects.
- Conditions
- Covid19-associated ARDS, Covid19, ARDS
- Trial name
- NCT04737486
- Testing
- AV-001
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vasomune Therapeutics, Inc.
Prevention of COVID-19 Variant (Omicron JN.1)
Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years
This Phase 1, multi-center, randomized, double-blind, placebo-controlled, dose-escalation study evaluates the safety, tolerability, and immunogenicity of BMI2012, a self-amplifying RNA vaccine candidate targeting the SARS-CoV-2…
- Trial name
- NCT07791186
- Testing
- BMI2012 low-dose, BMI2012 mid-dose, BMI2012 high-dose
- Where
- 3 sites in South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- BMI Korea
COVID-19
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with…
- Trial name
- NCT04333225
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Diseases, Chronic, Covid19
Safety and Immune Response of COVID-19 Vaccination in Patients With Basic Disease
On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19).Due to the…
- Conditions
- Diseases, Chronic, Covid19, Adverse Reaction to Vaccine
- Trial name
- SIM-PBD (NCT05043246)
- Testing
- SARS-COV-2 VACCINE
- Where
- China
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Covid19
Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)
SARS-CoV-2 is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute respiratory disease, collectively called coronavirus disease-19 (COVID-19).
- Trial name
- TP-SCB-2019001 (NCT05087368)
- Testing
- ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca), CoronaVac (Sinovac Biotech), Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)
- Where
- 3 sites in Brazil
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- D'Or Institute for Research and Education
Covid19
KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers
This is an First In Human (FIH), observer-blinded, randomized, placebo-controlled, parallel group study to evaluate the safety and immunogenicity of KBP-COVID-19 plus CPG adjuvant vaccine in healthy adult subjects in 2 age…
- Trial name
- NCT04473690
- Testing
- Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19
- Where
- 8 sites in United States, Canada
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- KBio Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.